

# Section 5

## 510(k) Summary

(in accordance with 21 CFR 807.92)

**Date: 27-JUL-2021**

**BK210620**

**Submitter:**

Alliance Technologies, LLC  
1552 W Griswold Road  
Phoenix, AZ 85021

**Contact:**

Susanne Logan  
Director of Quality and Regulatory Affairs  
Phone: 1-916-730-8685  
Fax: 1-602-492-2506  
Email: slogan@hemasystems.com

**Proposed Device Information:**

Trade Name: BloodRelay 1.1.0  
Common Name: Blood Establishment Computer Software (BECS) and Accessories  
Product Code: MMH  
Device: Stand-alone Blood Bank Software  
Review Panel: Hematology  
Device Class: Class II

**Predicate Device 1 Information:**

Trade Name: BloodRelay 1.0.0  
Common Name: Software, Blood Bank, Stand Alone  
510(k) Number: BK190361  
Product Code: MMH  
Device: Stand-alone Blood Bank Software  
Review Panel: Hematology  
Device Class: Unclassified

**Predicate Device 2 Information:**

Trade Name: Patient Health Software (P.H.S) v2.0  
Common Name: Software, Blood Bank, Stand Alone  
510(k) Number: BK180232  
Product Code: MMH  
Device: Stand-alone Blood Bank Software  
Review Panel: Hematology  
Device Class: Unclassified

**Device Description:**

BloodRelay is a software-only device. Blood product inventory transactions may be managed in the software. Records of blood unit processing and movement to other locations may be tracked. Inventory and all associated transactions may be searched for. Reference lab information may be recorded such as patient demographic information, sample information, and patient and product test results.

**Intended Use:**

BloodRelay is a blood bank application that may be used stand-alone. The system is designed to assist authorized and trained personnel who are actively engaged in the management of blood product inventory and patient records. Site-validated third-party systems may integrate with the system to support functions such as blood product inventory management.

The system supports operations for blood suppliers and reference labs such as inventory management and distribution of blood products, tracking product disposition, recording test results and searching for blood products. Blood product inventory may be quarantined.

**Indications for Use:**

BloodRelay is intended to integrate with site-validated third-party systems and assist authorized and trained blood bank personnel to:

Record and manage ISBT 128 blood product inventory associated information such as donation identification number (DIN), product code, expiration date/time, blood type and test results.

Record and manage blood product inventory dispositions such as shipment and quarantine.

Record, manage and search for patient demographic information such as name, date of birth, blood type, samples and test results.

Search and locate specific blood products to facilitate tasks such as quarantining inventory to remove unsuitable units, and assist in determining compatible products based on test results.

**Substantial Equivalence:**

The proposed BloodRelay v.1.1.0 software device is substantially equivalent to BloodRelay 1.0.0 (Predicate1) and Patient Health Software (P.H.S) 2.0 (Predicate 2). It has a similar intended use and technological features and capabilities. While there are minor differences in principles of operation and technology characteristics between the proposed BloodRelay v1.1.0 software device and the Predicate devices, no new questions of safety or effectiveness were raised.

The proposed BloodRelay v.1.1.0 software device is substantially equivalent to the Predicate devices listed in terms of intended use, functionality mapped, performance, technology characteristics, safety and effectiveness.

**Clinical Trials:**

Clinical performance testing is not applicable for BloodRelay 1.1.0 as it is a software only device.

**Conclusion:**

The proposed BloodRelay 1.1.0 software device was developed using an established design control process for software development based on 21 CFR part 820.30 Design Controls. The *Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices dated May, 2005* was also used. The proposed device was extensively tested at the verification and validation levels, including testing to ensure the proposed device meets its intended use including safety critical requirements. Beta testing was also completed at a user site to ensure user acceptance. The results of beta testing demonstrated that the proposed BloodRelay 1.1.0 software device meets required specifications and functions as expected with satisfactory performance times.

Based on the comparisons completed for mapped functionality, technology characteristics and intended use statements, the proposed BloodRelay 1.1.0 software device performs as intended. Safety features of the proposed BloodRelay 1.1.0 software device were tested according to practices specified in 21 CFR part 820.30 Design Controls, and all testing passed. The proposed BloodRelay 1.1.0 software device is substantially equivalent to the Predicate devices listed in terms of intended use, functionality mapped, performance, technology characteristics, safety and effectiveness.